FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

The FDA granted priority review to AstraZeneca's efzimfotase alfa for hypophosphatasia in patients aged two and older, with a decision expected in H1 2027 and a review period shortened by four months. The drug showed significant bone-health improvement in treatment-naive children in MULBERRY and maintained benefits for patients switching from Strensiq in CHESTNUT, although HICKORY missed its primary endpoint in treatment-naive patients aged 12 and older. A potential approval could extend AstraZeneca's HPP franchise, where Strensiq generated $1.05 billion of H1 2026 sales, up 41% year over year, while offering biweekly dosing versus Strensiq's three- or six-times-weekly regimen.

Analysis

The incremental value to AZN is primarily franchise defense rather than new-addressable-market creation. A lower-burden successor can reduce discontinuation and preserve pricing as the treated population ages, but switching an established enzyme-replacement population is more likely to shift revenue within AZN than generate immediate net sales growth. The relevant upside is longer treatment persistence and lower support-service intensity, which could modestly improve rare-disease margins over the 6-18 month post-launch period.

The key regulatory risk is label construction: the weaker result in older treatment-naive patients creates a plausible age-, onset-, or treatment-history limitation. A narrow label would materially reduce the commercial differentiation case, while a broad label would increase conversion pressure on AZN's legacy therapy and make the net revenue contribution more dependent on pricing and patient expansion than investor models may assume. Priority review is a timing signal, not independent validation of approvability.

BMRN and RXRX are not near-term competitive threats to AZN's cash flows; their relevance is strategic optionality around oral treatment and eventual payer preference for a non-injectable alternative. The contrarian view is that this news is too small to change AZN's earnings narrative in the next several quarters, particularly absent disclosed switching economics, manufacturing cost, and gross-to-net assumptions. The more actionable catalyst path is confirmation of label breadth and management guidance on cannibalization versus new-patient capture ahead of the expected decision.

Key Decisions for Investors

• Do not initiate a standalone AZN event trade on the review designation; the decision catalyst is too distant and the financial impact is unlikely to drive group-level estimates over the next 1-3 months.
• Maintain or add AZN only as a 6-18 month rare-disease franchise-defense position if valuation remains below large-cap pharma peers; require evidence at the next pipeline update that management expects net franchise expansion rather than substitution. Exit the thesis if guidance implies material net-price erosion or a restricted label.
• Use BMRN as a watch-list long rather than a funded short-versus-AZN pair: its oral HPP program has option value, but the missing data are human efficacy, durability, and safety. Reassess only after clinical data establish a credible biomarker and functional-benefit profile.
• For RXRX/RLYB, avoid assigning meaningful HPP value before an IND decision and initial human data. A positive development decision may create a short-term sentiment trade, but not an investable revenue catalyst; failure to advance the program would remove that optionality.